System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Meral Beksac is an expert in Hematology at Liv Hospital (Turkey). As of October 2026, ScienceLeadR ranks Meral Beksac in the top 1% of experts worldwide for Multiple Myeloma, Hemostatic Disorders and Paraproteinemias. Meral Beksac has authored 643 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 4 of them ongoing. SLR score: 2,681 (community average: 125). How the SLR is computed.

LeadR Profile

Meral Beksac Liv Hospital Turkey
2 681 ScienceLeadR Reputation 2681

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Ankara University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 643

Citations

Citations: 27 774 1st author: 55 Last author: 119 Unique author: 5

Main journals

Blood 154
CL LYMPH MYELOM LEUK 52
J Clin Oncol 50
Bone Marrow Transplant 26
Hemasphere 22

Best Journals

J Clin Oncol 24
Lancet Oncol 12
N Engl J Med 12

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study.
PMID 42882266 — mortality, troponin, cohort studies, amyloidosis, prognosis		Diagnostics (Basel)20260
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
PMID 42844619 — cells, hematology, progression-free survival, probability, multiple myeloma, network meta-analysis, therapeutics, t-lymphocytes		J Hematol Oncol Top journal20260
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
PMID 42789828 — safety, dexamethasone, bortezomib, multiple myeloma, lenalidomide, transplants		J Clin Oncol Top journal20260
How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature.
PMID 42604567 — therapeutics		Leuk Lymphoma20260
Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
PMID 42464352 — neoplasms, multiple myeloma, chromosomal instability		Mol Cancer Top journal20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 31
Phase 2 3
Phase 1/Phase 2 1

By status:

Completed 25
Active not recruiting 7
Recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 35

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 1
multicentricup10 31

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide Bortezomib Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515 — dexamethasone, bortezomib, multiple myeloma, antibodies, monoclonal, lenalidomide, therapeutics		Phase 3Active not recruiting2023
A Study to Evaluate Mezigdomide Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085 — dexamethasone, bortezomib, multiple myeloma, calcium, calcium dobesilate		Phase 3Recruiting2022
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320 — dexamethasone, aftercare, multiple myeloma, therapeutics		Phase 3Active not recruiting2022
Open label Study Comparing Iberdomide Daratumumab and Dexamethasone (IberDd) Versus Daratumumab Bortezomib and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997 — dexamethasone, bortezomib, multiple myeloma		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS